Ocular Compounds Mitigating Oxidative Stress in Retinal Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for treating retinal degenerations such as age-related macular degeneration (AMD) and anterior segment disorders like Fuchs endothelial corneal dystrophy, cataracts, glaucoma, and keratoconus, as they fail to effectively slow or prevent disease progression.
Innovation Solution
Administration of pharmaceutical compositions containing specific compounds, such as ciclopirox olamine, piroctone, and imidazopyrimidine/imidazopyrazine derivatives, which are formulated for ocular administration and are designed to protect retinal cells from oxidative stress-induced cell death, enhance mitochondrial function, and promote cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat retinal degenerations and anterior segment disorders, then current treatment standards are maintained, but disease progression is not effectively slowed or prevented
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antioxidant compounds (formula (1) with specific R1 and R2 groups, formula (2) with imidazopyrimidine/imidazopyrazine cores) to enhance their biological activity and efficacy in slowing disease progression while maintaining safety profiles
Solution Approach 2:
The patent combines multiple therapeutic agents (compounds of formula (1) and formula (2), and their combinations) to achieve synergistic effects that improve disease progression control beyond what single agents can accomplish alone
2Reliability
If oxidative stress is reduced to protect retinal and corneal cells, then cell viability is enhanced, but the complexity of therapeutic regimens increases
Solution Approach 1:
The patent segments the therapeutic approach into two distinct compound classes (formula (1) with pyridone derivatives and formula (2) with imidazopyrimidine/imidazopyrazine derivatives), each targeting oxidative stress through different mechanisms, allowing for systematic development and optimization of each agent
Solution Approach 2:
The patent identifies oxidative stress as the key intermediary pathway linking multiple ocular diseases (AMD, RP, FECD, cataracts, glaucoma, keratoconus) and develops compounds that specifically target this common mechanism, simplifying treatment strategies by addressing a universal pathogenic factor
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds and methods effectively protect retinal and corneal cells from oxidative stress, improve mitochondrial function, and enhance cell viability, thereby slowing or preventing the progression of retinal and anterior segment disorders.
Implementation Method 1
Oxidative stress is a contributing factor to these changes and has been implicated in other diseases in which aging is a risk factor, including Alzheimer's disease and Parkinson's disease. In addition, Mendelian disorders, such as most forms of RP, can be accelerated by the presence of oxidative stress.
Implementation Method 2
Diseases of the anterior segment including the cornea, lens, and trabecular meshwork are leading causes of blindness worldwide. Oxidative stress and mitochondrial function has been implicated in these anterior segment diseases
Data Source
AI summary
The invention provides a method of treating retinal degenerations, such as but not limited to anterior segment ocular disorders and/or age-related macular degeneration (AMD), in a subject, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of a compound of formula (1) or formula (2). In a further aspect, the invention provides compounds of formula (2). In certain embodiments, the compounds of the invention prevent or minimize cellular assault, such as oxidative stress-related cellular assault, and/or promote cell viability.